You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Resected Invasive Urothelial Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma, Urothelial Carcinoma Trial in Berlin (Nivolumab/rHuPH20, Nivolumab)

Not yet recruiting
  • Melanoma
  • Urothelial Carcinoma
  • Berlin, Germany
    Local Institution - 0001
Aug 9, 2022

Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)

Not yet recruiting
  • Urothelial Carcinoma Bladder
  • Androgen Receptor Positive
  • Providence, Rhode Island
    Lifespan Cancer Institute
May 1, 2023

Nivolumab in Japanese Muscle-invasive Urothelial Carcinoma

Not yet recruiting
  • Muscle-invasive Urothelial Carcinoma
    • City, State, Japan
      Local Institution
    Mar 20, 2023

    High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma, Perfusion; Complications, Intraoperative Complications Trial

    Recruiting
    • High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma
    • +2 more
    • hyperthermic intravesical perfusion
    • Zhengzhou, Henan, China
      BR-PRG
    Sep 15, 2022

    Urothelial Carcinoma Trial in Sohag (Expression of Cortactin anti body)

    Completed
    • Urothelial Carcinoma
    • Expression of Cortactin anti body
    • Sohag, Egypt
      Maisa Hashem Mohammed
    Jul 13, 2022

    Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma Trial in Tampa (Adoptive Cell Therapy with Tumor-infiltrating

    Recruiting
    • Urothelial Carcinoma
    • Non-Invasive Bladder Urothelial Carcinoma
    • Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
    • Tampa, Florida
      Moffitt Cancer Center
    Mar 2, 2023

    Muscle Invasive Bladder Cancer, Urothelial Carcinoma Trial in Tianjin (Tislelizumab, Nab paclitaxel)

    Active, not recruiting
    • Muscle Invasive Bladder Cancer
    • Urothelial Carcinoma
    • Tianjin, Tianjin, China
      Tianjin Medical University Second Hospital
    Nov 23, 2022

    Preferences for Japanese Muscle-invasive Urothelial Carcinoma of

    Not yet recruiting
    • Urinary Bladder Neoplasms
      • (no location specified)
      Feb 14, 2023

      Urothelial Carcinoma Trial in France, Italy, United States (retifanlimab, epacadostat, INCAGN02385)

      Recruiting
      • Urothelial Carcinoma
      • Iowa City, Iowa
      • +11 more
      Dec 1, 2022

      Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma Trial (Pembrolizumab)

      Recruiting
      • Muscle Invasive Bladder Carcinoma
      • +2 more
      • Indianapolis, Indiana
      • +1 more
      Jan 12, 2023

      Protocol for Muscle Invasive Urothelial Carcinoma of Urinary

      Recruiting
      • Bladder Cancer
      • terta modal bladder preservation
      • Assiut, Assuit, Egypt
        Assuit university
      Aug 13, 2022

      Radical Cystectomy, Urothelial Carcinoma Trial in Wuhan (Disitamab Vedotin and Gemcitabine)

      Recruiting
      • Radical Cystectomy
      • Urothelial Carcinoma
      • Disitamab Vedotin and Gemcitabine
      • Wuhan, Hubei, China
      • +1 more
      Feb 9, 2023

      Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma Trial in Tianjin (Disitamab Vedotin Tislelizumab,

      Recruiting
      • Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
      • Disitamab Vedotin Tislelizumab
      • Disitamab Vedotin
      • Tianjin, Tianjin, China
        Tianjin Medical University Second Hospital
      Aug 9, 2022

      Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma,

      Active, not recruiting
      • Hydronephrosis
      • +18 more
      • Durvalumab
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Oct 31, 2022

      Intravesical BCG: is the Urinary Bladder Ready to Receive it

      Not yet recruiting
      • Non-Invasive Bladder Urothelial Carcinoma
        • (no location specified)
        Jun 7, 2022

        High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma Trial in Tianjin (Tislelizumab Nab paclitaxel)

        Recruiting
        • High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
        • Tislelizumab Nab paclitaxel
        • Tianjin, Tianjin, China
          Tianjin Medical University Second Hospital
        Jun 9, 2022

        Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma Trial in New York (BGJ398)

        Active, not recruiting
        • Bladder Cancer
        • Non-Muscle-Invasive Urothelial Carcinoma
        • New York, New York
          Memorial Sloan Kettering Cancer Center
        Feb 3, 2022

        Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma, High Risk Non-Muscle Invasive Bladder

        Not yet recruiting
        • Non-muscle-invasive Bladder Cancer
        • +2 more
        • PDD-TURBT with hexaminolevulinate (Hexvix®)
        • Power Led Saphira (TM) from KARL STORZ
        • (no location specified)
        Jul 24, 2023

        Upper Tract Urinary Carcinoma, Muscle-invasive Bladder Cancer Trial in Beijing (Toripalimab)

        Recruiting
        • Upper Tract Urinary Carcinoma
        • Muscle-invasive Bladder Cancer
        • Beijing, Beijing, China
          Cancer Institute and Hospital, Chinese Academy of Medical Scienc
        Mar 12, 2022

        Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 Trial in Seattle

        Recruiting
        • Muscle Invasive Bladder Carcinoma
        • +2 more
        • Lymphadenectomy
        • +2 more
        • Seattle, Washington
          Fred Hutch/University of Washington Cancer Consortium
        Jan 9, 2023

        Urothelial Carcinoma Trial (Disitamab Vedotin, radiotherapy)

        Not yet recruiting
        • Urothelial Carcinoma
        • Disitamab Vedotin
        • radiotherapy
        • (no location specified)
        Jun 20, 2023

        Urothelial Carcinoma, Bladder Cancer Trial in United States (drug, radiation, biological)

        Recruiting
        • Urothelial Carcinoma
        • Bladder Cancer
        • Durvalumab (Cohort 1-3)
        • +7 more
        • Phoenix, Arizona
        • +10 more
        Jan 11, 2023

        Urothelial Bladder Carcinoma Trial in Spain (Sacituzumab govitecan, Zimberelimab, Domvanalimab)

        Not yet recruiting
        • Urothelial Bladder Carcinoma
        • Sacituzumab govitecan
        • +2 more
        • Santiago De Compostela, A Coruña, Spain
        • +9 more
        Nov 14, 2023

        Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma Trial in Cleveland (Sacituzumab

        Not yet recruiting
        • Localized Muscle Invasive Bladder Urothelial Carcinoma
        • Muscle-Invasive Bladder Carcinoma
        • Sacituzumab govitecan
        • Adaptive Radiotherapy
        • Cleveland, Ohio
          Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
        Apr 18, 2023

        Muscle-invasive Urothelial Carcinoma of the Bladder Trial in Milan (Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA])

        Not yet recruiting
        • Muscle-invasive Urothelial Carcinoma of the Bladder
        • Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]
        • Milan, MI, Italy
          Fondazione San Raffaele
        Sep 8, 2022